TY - JOUR
T1 - Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing
T2 - A double-blind, randomized, placebo-controlled trial
AU - Fonseca-Aten, Monica
AU - Okada, Pamela J.
AU - Bowlware, Karen L.
AU - Chavez-Bueno, Susana
AU - Mejias, Asuncion
AU - Rios, Ana Maria
AU - Katz, Kathy
AU - Olsen, Kurt
AU - Ng, Simon
AU - Jafri, Hasan S.
AU - McCracken, George H.
AU - Ramilo, Octavio
AU - Hardy, R. Doug
N1 - Funding Information:
This study was supported in part by grants from Abbott Laboratories Inc and Children’s Medical Center of Dallas Research Advisory Committee.
PY - 2006/10
Y1 - 2006/10
N2 - Background: Clarithromycin is postulated to possess immunomodulatory properties in addition to its antimicrobial activity. Objective: To evaluate the effect of clarithromycin on serum and nasopharyngeal cytokine and chemokine concentrations in children with an acute exacerbation of recurrent wheezing. Methods: Children with a history of recurrent wheezing or asthma and who presented with an acute exacerbation of wheezing were enrolled in a double-blind, randomized trial of clarithromycin vs placebo. Concentrations of tumor necrosis factor a (TNF-α), interferon-γ (IFN-γ), interleukin-1β (IL-1β), IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, granulocyte-macrophage colony-stimulating factor, RANTES, eotaxin, macrophage inflammatory protein 1α, macrophage inflammatory protein 1β, and monocyte chemoattractant protein 1 were measured in serum and/or nasopharyngeal aspirates before, during, and after therapy. Mycoplasma pneumoniae and Chlamydophila pneumoniae infection were evaluated for by polymerase chain reaction and serologic testing. Results: Nasopharyngeal concentrations of TNF-α, IL-1β, and IL-10 were significantly and persistently lower in children treated with clarithromycin compared with placebo. There tended to be a greater effect of clarithromycin on nasopharyngeal cytokine concentrations in patients with evidence of C pneumoniae or C pneumoniae infection. No significant differences were detected in serum cytokines for children treated with clarithromycin compared with placebo. Conclusion: Clarithromycin therapy reduces mucosal TNF-α, IL-1β, and IL-10 concentrations in children with an acute exacerbation of recurrent wheezing.
AB - Background: Clarithromycin is postulated to possess immunomodulatory properties in addition to its antimicrobial activity. Objective: To evaluate the effect of clarithromycin on serum and nasopharyngeal cytokine and chemokine concentrations in children with an acute exacerbation of recurrent wheezing. Methods: Children with a history of recurrent wheezing or asthma and who presented with an acute exacerbation of wheezing were enrolled in a double-blind, randomized trial of clarithromycin vs placebo. Concentrations of tumor necrosis factor a (TNF-α), interferon-γ (IFN-γ), interleukin-1β (IL-1β), IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, granulocyte-macrophage colony-stimulating factor, RANTES, eotaxin, macrophage inflammatory protein 1α, macrophage inflammatory protein 1β, and monocyte chemoattractant protein 1 were measured in serum and/or nasopharyngeal aspirates before, during, and after therapy. Mycoplasma pneumoniae and Chlamydophila pneumoniae infection were evaluated for by polymerase chain reaction and serologic testing. Results: Nasopharyngeal concentrations of TNF-α, IL-1β, and IL-10 were significantly and persistently lower in children treated with clarithromycin compared with placebo. There tended to be a greater effect of clarithromycin on nasopharyngeal cytokine concentrations in patients with evidence of C pneumoniae or C pneumoniae infection. No significant differences were detected in serum cytokines for children treated with clarithromycin compared with placebo. Conclusion: Clarithromycin therapy reduces mucosal TNF-α, IL-1β, and IL-10 concentrations in children with an acute exacerbation of recurrent wheezing.
UR - http://www.scopus.com/inward/record.url?scp=33750143784&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750143784&partnerID=8YFLogxK
U2 - 10.1016/S1081-1206(10)60935-0
DO - 10.1016/S1081-1206(10)60935-0
M3 - Article
C2 - 17069099
AN - SCOPUS:33750143784
SN - 1081-1206
VL - 97
SP - 457
EP - 463
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 4
ER -